Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets
Vertex Pharmaceuticals Deferred Tax Assets and Other Non-Current Assets increased by 1.6% to $1.26B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 24.7%, from $1.01B to $1.26B. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets and Other Non-Current Assets shows an upward trend with a 90.5% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryLiquidity
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase generally reflects a growing long-term asset base or deferred tax position, while a decrease suggests asset liquidation or tax benefit utilization.
Detailed definition
This is the aggregate balance of non-current deferred tax assets and other miscellaneous non-current assets not classifi...
Peer comparison
Commonly found in the non-current asset section of balance sheets for large, diversified financial firms.
Metric ID:
deferred_tax_assets_other_noncurrentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $71.10M | $75.52M | $110.80M | $110.70M | $127.30M | $132.50M | $409.60M | $427.50M | $442.70M | $475.20M | $895.30M | $875.70M | $915.60M | $990.20M | $999.30M | $1.01B | $1.08B | $1.10B | $1.24B | $1.26B |
| QoQ Change | — | +6.2% | +46.7% | -0.1% | +15.0% | +4.1% | +209.1% | +4.4% | +3.6% | +7.3% | +88.4% | -2.2% | +4.6% | +8.1% | +0.9% | +0.8% | +7.1% | +1.8% | +12.6% | +1.6% |
| YoY Change | — | — | — | — | +79.0% | +75.5% | +269.7% | +286.2% | +247.8% | +258.6% | +118.6% | +104.8% | +106.8% | +108.4% | +11.6% | +15.0% | +17.8% | +10.9% | +23.7% | +24.7% |
Range$71.10M – $1.26B
CAGR+83.1%
Avg YoY Growth+110.0%
Median YoY Growth+91.9%
Current Streak8 quarters growth
Deferred Tax Assets and Other Non-Current Assets at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's deferred tax assets and other non-current assets?
- Vertex Pharmaceuticals (VRTX) reported deferred tax assets and other non-current assets of $1.26B in Q1 2026.
- How has Vertex Pharmaceuticals's deferred tax assets and other non-current assets changed year-over-year?
- Vertex Pharmaceuticals's deferred tax assets and other non-current assets increased by 24.7% year-over-year, from $1.01B to $1.26B.
- What is the long-term trend for Vertex Pharmaceuticals's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's deferred tax assets and other non-current assets has grown at a 90.5% compound annual growth rate (CAGR), from $49.30M to $1.24B.
- What does deferred tax assets and other non-current assets mean?
- The total value of long-term tax assets and other miscellaneous long-term assets.